Pain Pumps

Anonymous · Jan 6, 2014 at 12:03 PM

Anonymous said: ↑

Fixed your post, you pharma puppet. Glad I sold my stock at $58. The end is near
Click to expand...

dont go away mad…just go away

Anonymous · Feb 3, 2014 at 10:11 PM

Anonymous said: ↑

Fixed your post, you pharma puppet. Glad I sold my stock at $58. The end is near
Click to expand...

Sold too soon! PCRX will put you out of business!!

Anonymous · Feb 6, 2014 at 10:41 AM

You chumps don't seem to understand that the monkey died and the show is over. When the "bogus spinoff" comes, all of you will be looking for a job! Gets some smarts and get out while the getting is good.

Anonymous · Feb 12, 2014 at 11:57 AM

Anonymous said: ↑

As a clinician I hope you are sharing this information with your surgeons. I am happy for your success however different modalities offer surgeons options. Why is it so hard to work together and ensure the patient has the best outcome always?

8.2 Adverse Reactions Reported in All Wound Infiltration Clinical Studies

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The safety of bupivacaine liposome suspension was evaluated in 10 randomized, double-blind, local administration into the surgical site clinical studies involving 823 patients undergoing various surgical procedures. Patients were administered a dose ranging from 66 to 532 mg of bupivacaine liposome suspension. In these studies, the most common adverse reactions (incidence greater than or equal to 10%) following bupivacaine liposome suspension administration were nausea, constipation, and vomiting.

The common adverse reactions (incidence greater than or equal to 2% to less than 10%) following bupivacaine liposome suspension administration were pyrexia, dizziness, edema peripheral, anemia, hypotension, pruritus, tachycardia, headache, insomnia, anemia postoperative, muscle spasms, hemorrhagic anemia, back pain, somnolence, and procedural pain.

The less common/rare adverse reactions (incidence less than 2%) following bupivacaine liposome suspension administration were chills, erythema, bradycardia, anxiety, urinary retention, pain, edema, tremor, dizziness postural, paresthesia, syncope, incision site edema, procedural hypertension, procedural hypotension, procedural nausea, muscular weakness, neck pain, pruritus generalized, rash pruritic, hyperhidrosis, cold sweat, urticaria, bradycardia, palpitations, sinus bradycardia, supraventricular extrasystoles, ventricular extrasystoles, ventricular tachycardia, hypertension, pallor, anxiety, confusional state, depression, agitation, restlessness, hypoxia, laryngospasm, apnea, respiratory depression, respiratory failure, body temperature increased, blood pressure increased, blood pressure decreased, oxygen saturation decreased, urinary retention, urinary incontinence, vision blurred, tinnitus, drug hypersensitivity, and hypersensitivity.

Neurological and Cardiac Adverse Reactions Reported in All Wound Infiltration Clinical Studies

In the bupivacaine liposome suspension wound infiltration studies, adverse reactions with an incidence greater than or equal to 1% in the Nervous System Disorders system organ class following bupivacaine liposome suspension administration were dizziness (6.2%), headache (3.8%), somnolence (2.1%), hypoesthesia (1.5%), and lethargy (1.3%). The adverse reactions with an incidence greater than or equal to 1% in the Cardiac Disorders system organ class following bupivacaine liposome suspension administration were tachycardia (3.9%) and bradycardia (1.6%).
Click to expand...

Hey dip shit, you using the product yet or are all the docs passing you bye?

Anonymous · Feb 27, 2014 at 10:37 PM

6:30 am Pacira Pharma announces EXPAREL Phase 3 clinical trial in femoral nerve block meets primary efficacy endpoint; sNDA submission expected in second quarter of 2014 with a 10-month PDUFA timeline (PCRX) : Co announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint. This pivotal Phase 3 trial evaluated 183 patients who were randomized to receive either 266 mg of EXPAREL or placebo, with all patients offered rescue narcotics as needed. Results demonstrated statistical significance in favor of EXPAREL for cumulative pain scores over 72 hours as measured by the area under the curve AUC)

OUCH! OnQ another day closer to the end

Anonymous · Feb 28, 2014 at 11:10 AM

You mooks selling this pos are second day news Give it up, you will be sold off inside of six months. Another great purchase by Joanne Bauers!!!

Pain Pumps

Anonymous Guest

Anonymous Guest

Anonymous Guest

Anonymous Guest

Anonymous Guest

Anonymous Guest

Useful Searches

Pain Pumps

Anonymous Guest

Anonymous Guest

Anonymous Guest

Anonymous Guest

Anonymous Guest

Anonymous Guest